Sovateltide

N/A

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameSovateltide
Drug Alias NameTyvalziPMZ-1620SPI-1620IRL-1620
ClassificationDiagnostic agent (In vivo)Small molecules > Synthetic peptide
Mechanisms of ActionDiagnostic imaging enhancersNeurogenesis stimulantsEndothelin receptor type B agonists +[5] 
TargetsEndothelin receptor type B
Therapy Area/IndicationsIschemic StrokeAsphyxia NeonatorumSpinal Cord Injuries +[12] 
Global Approved IndicationsStroke
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2023/05/31
Country/TerritoryUnited StatesGermanyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Illinois At Chicago
China Registration ClassN/A

Develop Information

Active CompaniesPharmazz Inc
Inactive CompaniesSpectrum Pharmaceuticals Inc
Active IndicationsIschemic StrokeAsphyxia NeonatorumSpinal Cord Injuries +[9] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungBiliary Tract NeoplasmsCarcinoma

Other Information

ATC CodeN/A
Related LinksWikipedia